GABAergic inhibition in dual-transmission cholinergic and GABAergic striatal interneurons is abolished in Parkinson disease. 2018

N Lozovaya, and S Eftekhari, and R Cloarec, and L A Gouty-Colomer, and A Dufour, and B Riffault, and M Billon-Grand, and A Pons-Bennaceur, and N Oumar, and N Burnashev, and Y Ben-Ari, and C Hammond
B&A Therapeutics, Ben-Ari Institute of Neuroarcheology, Batiment Beret-Delaage, zone Luminy entreprises, 13288, Marseille, Cedex 09, France.

We report that half striatal cholinergic interneurons are dual transmitter cholinergic and GABAergic interneurons (CGINs) expressing ChAT, GAD65, Lhx7, and Lhx6 mRNAs, labeled with GAD and VGAT, generating monosynaptic dual cholinergic/GABAergic currents and an inhibitory pause response. Dopamine deprivation increases CGINs ongoing activity and abolishes GABAergic inhibition including the cortico-striatal pause because of high [Cl-]i levels. Dopamine deprivation also dramatically increases CGINs dendritic arbors and monosynaptic interconnections probability, suggesting the formation of a dense CGINs network. The NKCC1 chloride importer antagonist bumetanide, which reduces [Cl-]i levels, restores GABAergic inhibition, the cortico-striatal pause-rebound response, and attenuates motor effects of dopamine deprivation. Therefore, most of the striatal cholinergic excitatory drive is balanced by a concomitant powerful GABAergic inhibition that is impaired by dopamine deprivation. The attenuation by bumetanide of cardinal features of Parkinson's disease paves the way to a novel therapeutic strategy based on a restoration of low [Cl-]i levels and GABAergic inhibition.

UI MeSH Term Description Entries
D007395 Interneurons Most generally any NEURONS which are not motor or sensory. Interneurons may also refer to neurons whose AXONS remain within a particular brain region in contrast to projection neurons, which have axons projecting to other brain regions. Intercalated Neurons,Intercalated Neuron,Interneuron,Neuron, Intercalated,Neurons, Intercalated
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D009419 Nerve Tissue Proteins Proteins, Nerve Tissue,Tissue Proteins, Nerve
D009473 Neuronal Plasticity The capacity of the NERVOUS SYSTEM to change its reactivity as the result of successive activations. Brain Plasticity,Plasticity, Neuronal,Axon Pruning,Axonal Pruning,Dendrite Arborization,Dendrite Pruning,Dendritic Arborization,Dendritic Pruning,Dendritic Remodeling,Neural Plasticity,Neurite Pruning,Neuronal Arborization,Neuronal Network Remodeling,Neuronal Pruning,Neuronal Remodeling,Neuroplasticity,Synaptic Plasticity,Synaptic Pruning,Arborization, Dendrite,Arborization, Dendritic,Arborization, Neuronal,Arborizations, Dendrite,Arborizations, Dendritic,Arborizations, Neuronal,Axon Prunings,Axonal Prunings,Brain Plasticities,Dendrite Arborizations,Dendrite Prunings,Dendritic Arborizations,Dendritic Prunings,Dendritic Remodelings,Network Remodeling, Neuronal,Network Remodelings, Neuronal,Neural Plasticities,Neurite Prunings,Neuronal Arborizations,Neuronal Network Remodelings,Neuronal Plasticities,Neuronal Prunings,Neuronal Remodelings,Neuroplasticities,Plasticities, Brain,Plasticities, Neural,Plasticities, Neuronal,Plasticities, Synaptic,Plasticity, Brain,Plasticity, Neural,Plasticity, Synaptic,Pruning, Axon,Pruning, Axonal,Pruning, Dendrite,Pruning, Dendritic,Pruning, Neurite,Pruning, Neuronal,Pruning, Synaptic,Prunings, Axon,Prunings, Axonal,Prunings, Dendrite,Prunings, Dendritic,Prunings, Neurite,Prunings, Neuronal,Prunings, Synaptic,Remodeling, Dendritic,Remodeling, Neuronal,Remodeling, Neuronal Network,Remodelings, Dendritic,Remodelings, Neuronal,Remodelings, Neuronal Network,Synaptic Plasticities,Synaptic Prunings
D010302 Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42) Atherosclerotic Parkinsonism,Secondary Parkinsonism,Symptomatic Parkinson Disease,Parkinson Disease, Secondary Vascular,Parkinson Disease, Symptomatic,Parkinsonism, Secondary,Parkinsonism, Symptomatic,Secondary Vascular Parkinson Disease,Parkinsonism, Atherosclerotic,Secondary Parkinson Disease,Symptomatic Parkinsonism
D002034 Bumetanide A sulfamyl diuretic. Bumedyl,Bumethanide,Bumex,Burinex,Drenural,Fordiuran,Miccil,PF-1593,PF 1593,PF1593
D002712 Chlorides Inorganic compounds derived from hydrochloric acid that contain the Cl- ion. Chloride,Chloride Ion Level,Ion Level, Chloride,Level, Chloride Ion
D003342 Corpus Striatum Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE. Lenticular Nucleus,Lentiform Nucleus,Lentiform Nuclei,Nucleus Lentiformis,Lentiformis, Nucleus,Nuclei, Lentiform,Nucleus, Lenticular,Nucleus, Lentiform,Striatum, Corpus
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D005680 gamma-Aminobutyric Acid The most common inhibitory neurotransmitter in the central nervous system. 4-Aminobutyric Acid,GABA,4-Aminobutanoic Acid,Aminalon,Aminalone,Gammalon,Lithium GABA,gamma-Aminobutyric Acid, Calcium Salt (2:1),gamma-Aminobutyric Acid, Hydrochloride,gamma-Aminobutyric Acid, Monolithium Salt,gamma-Aminobutyric Acid, Monosodium Salt,gamma-Aminobutyric Acid, Zinc Salt (2:1),4 Aminobutanoic Acid,4 Aminobutyric Acid,Acid, Hydrochloride gamma-Aminobutyric,GABA, Lithium,Hydrochloride gamma-Aminobutyric Acid,gamma Aminobutyric Acid,gamma Aminobutyric Acid, Hydrochloride,gamma Aminobutyric Acid, Monolithium Salt,gamma Aminobutyric Acid, Monosodium Salt

Related Publications

N Lozovaya, and S Eftekhari, and R Cloarec, and L A Gouty-Colomer, and A Dufour, and B Riffault, and M Billon-Grand, and A Pons-Bennaceur, and N Oumar, and N Burnashev, and Y Ben-Ari, and C Hammond
May 2018, Cell stress,
N Lozovaya, and S Eftekhari, and R Cloarec, and L A Gouty-Colomer, and A Dufour, and B Riffault, and M Billon-Grand, and A Pons-Bennaceur, and N Oumar, and N Burnashev, and Y Ben-Ari, and C Hammond
March 2014, Neuroscience,
N Lozovaya, and S Eftekhari, and R Cloarec, and L A Gouty-Colomer, and A Dufour, and B Riffault, and M Billon-Grand, and A Pons-Bennaceur, and N Oumar, and N Burnashev, and Y Ben-Ari, and C Hammond
August 2017, Journal of neurochemistry,
N Lozovaya, and S Eftekhari, and R Cloarec, and L A Gouty-Colomer, and A Dufour, and B Riffault, and M Billon-Grand, and A Pons-Bennaceur, and N Oumar, and N Burnashev, and Y Ben-Ari, and C Hammond
May 2018, The European journal of neuroscience,
N Lozovaya, and S Eftekhari, and R Cloarec, and L A Gouty-Colomer, and A Dufour, and B Riffault, and M Billon-Grand, and A Pons-Bennaceur, and N Oumar, and N Burnashev, and Y Ben-Ari, and C Hammond
October 2016, Cerebral cortex (New York, N.Y. : 1991),
N Lozovaya, and S Eftekhari, and R Cloarec, and L A Gouty-Colomer, and A Dufour, and B Riffault, and M Billon-Grand, and A Pons-Bennaceur, and N Oumar, and N Burnashev, and Y Ben-Ari, and C Hammond
January 1994, Journal of neurochemistry,
N Lozovaya, and S Eftekhari, and R Cloarec, and L A Gouty-Colomer, and A Dufour, and B Riffault, and M Billon-Grand, and A Pons-Bennaceur, and N Oumar, and N Burnashev, and Y Ben-Ari, and C Hammond
December 2011, Nature neuroscience,
N Lozovaya, and S Eftekhari, and R Cloarec, and L A Gouty-Colomer, and A Dufour, and B Riffault, and M Billon-Grand, and A Pons-Bennaceur, and N Oumar, and N Burnashev, and Y Ben-Ari, and C Hammond
January 2013, Frontiers in systems neuroscience,
N Lozovaya, and S Eftekhari, and R Cloarec, and L A Gouty-Colomer, and A Dufour, and B Riffault, and M Billon-Grand, and A Pons-Bennaceur, and N Oumar, and N Burnashev, and Y Ben-Ari, and C Hammond
January 2015, Frontiers in cellular neuroscience,
N Lozovaya, and S Eftekhari, and R Cloarec, and L A Gouty-Colomer, and A Dufour, and B Riffault, and M Billon-Grand, and A Pons-Bennaceur, and N Oumar, and N Burnashev, and Y Ben-Ari, and C Hammond
June 2015, Neurobiology of disease,
Copied contents to your clipboard!